Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
71.86
+2.68 (3.87%)
At close: Mar 9, 2026, 4:00 PM EDT
73.29
+1.43 (1.99%)
After-hours: Mar 9, 2026, 5:11 PM EDT
Inhibrx Biosciences Market Cap
Inhibrx Biosciences has a market cap or net worth of $1.05 billion as of March 9, 2026. Its market cap has increased by 464.04% in one year.
Market Cap
1.05B
Enterprise Value
961.41M
1-Year Change
464.04%
Ranking
Category
Stock Price
$71.86
Market Cap Chart
Since the IPO on May 29, 2024, Inhibrx Biosciences's market cap has increased from $198.24M to $1.05B, an increase of 427.20%. That is a compound annual growth rate of 155.82%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 1.01B | -12.43% |
| Dec 31, 2025 | 1.15B | 415.39% |
| Dec 31, 2024 | 222.93M | 12.46% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Pharming Group | 1.06B |
| AbCellera Biologics | 1.05B |
| ArriVent BioPharma | 1.04B |
| Xeris Biopharma Holdings | 1.00B |
| UroGen Pharma | 996.04M |
| Compass Therapeutics | 992.28M |
| GH Research | 988.13M |
| Aktis Oncology | 987.94M |